Leerink Partnrs Has Pessimistic View of VYGR Q2 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at Leerink Partnrs reduced their Q2 2025 earnings estimates for Voyager Therapeutics in a research note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will post earnings of ($0.45) per share for the quarter, down from their previous estimate of ($0.17). The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.80) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($1.35) EPS and FY2028 earnings at ($0.67) EPS.

A number of other brokerages have also weighed in on VYGR. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, April 8th. Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an "overweight" rating in a research report on Wednesday, March 12th. Canaccord Genuity Group dropped their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $13.97.

Voyager Therapeutics Price Performance

NASDAQ VYGR traded up $0.18 on Friday, hitting $3.35. The stock had a trading volume of 662,542 shares, compared to its average volume of 446,728. The business's fifty day moving average price is $3.50 and its 200 day moving average price is $4.89. Voyager Therapeutics has a 52-week low of $2.75 and a 52-week high of $9.55. The stock has a market cap of $185.30 million, a price-to-earnings ratio of 4.72 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The business had revenue of $6.47 million for the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its holdings in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company's stock valued at $612,000 after acquiring an additional 37,398 shares during the last quarter. SG Americas Securities LLC raised its position in Voyager Therapeutics by 86.7% in the fourth quarter. SG Americas Securities LLC now owns 23,044 shares of the company's stock valued at $131,000 after purchasing an additional 10,704 shares during the period. Empowered Funds LLC increased its position in shares of Voyager Therapeutics by 5.3% during the fourth quarter. Empowered Funds LLC now owns 47,206 shares of the company's stock worth $268,000 after acquiring an additional 2,397 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Voyager Therapeutics by 23.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock worth $223,000 after acquiring an additional 7,573 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Voyager Therapeutics by 3.4% during the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after acquiring an additional 2,354 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.

Insider Buying and Selling at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.39% of the stock is owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.